EA201390070A1 - Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина - Google Patents
Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофаминаInfo
- Publication number
- EA201390070A1 EA201390070A1 EA201390070A EA201390070A EA201390070A1 EA 201390070 A1 EA201390070 A1 EA 201390070A1 EA 201390070 A EA201390070 A EA 201390070A EA 201390070 A EA201390070 A EA 201390070A EA 201390070 A1 EA201390070 A1 EA 201390070A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dopamine
- dopa
- treatment
- amplifier
- agonist
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 9
- 229960003638 dopamine Drugs 0.000 title abstract 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- CTYOUOHIEXEYAW-MEVSNGMESA-N furostane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H]3O[C@H](CCC(C)C)[C@@H](C)[C@@H]3[C@@]1(C)CC2 CTYOUOHIEXEYAW-MEVSNGMESA-N 0.000 abstract 2
- FRPYMMBAAIXFOI-UHFFFAOYSA-N furostane Natural products CC(CCC1(O)OC2CC3C4CCC5CC(OC6OC(C)C(O)C(O)C6OC7OC(C)C(O)C(O)C7O)C(O)CC5(C)C4CCC3(C)C2C1C)COC8OC(CO)C(O)C(O)C8O FRPYMMBAAIXFOI-UHFFFAOYSA-N 0.000 abstract 2
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36601510P | 2010-07-20 | 2010-07-20 | |
| PCT/GB2011/051376 WO2012010896A1 (en) | 2010-07-20 | 2011-07-20 | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201390070A1 true EA201390070A1 (ru) | 2013-09-30 |
Family
ID=44583771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390070A EA201390070A1 (ru) | 2010-07-20 | 2011-07-20 | Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130210786A1 (https=) |
| EP (1) | EP2595621A1 (https=) |
| JP (1) | JP2013543482A (https=) |
| KR (1) | KR20130043197A (https=) |
| CN (1) | CN103189056A (https=) |
| AU (1) | AU2011281336B2 (https=) |
| BR (1) | BR112013001422A2 (https=) |
| CA (1) | CA2805693A1 (https=) |
| EA (1) | EA201390070A1 (https=) |
| MX (1) | MX2013000760A (https=) |
| SG (1) | SG187090A1 (https=) |
| WO (1) | WO2012010896A1 (https=) |
| ZA (1) | ZA201301231B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20110244A7 (es) * | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios |
| PL2854764T3 (pl) | 2012-06-05 | 2019-07-31 | Neuroderm Ltd | Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania |
| WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
| JP2017008044A (ja) * | 2015-06-22 | 2017-01-12 | 学校法人 久留米大学 | ドーパミンシグナル伝達の抑制剤 |
| CN105106230A (zh) * | 2015-08-16 | 2015-12-02 | 南京华宽信息咨询中心 | 一种单胺氧化酶mao抑制剂及其应用 |
| BR112022001595A2 (pt) * | 2019-07-29 | 2022-03-22 | Peptron Inc | Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| KR102528677B1 (ko) * | 2020-01-08 | 2023-05-04 | 주식회사 뉴로벤티 | 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| MX2023000314A (es) * | 2020-08-17 | 2023-02-22 | Pike Therapeutics Inc | Formulaciones farmaceuticas transdermicas de cannabinoides. |
| CN115282156A (zh) * | 2022-09-05 | 2022-11-04 | 广东海洋大学 | 知母皂苷元在制备防治帕金森病的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA985172A (en) | 1972-10-06 | 1976-03-09 | Dushan M. Dvornik | Compositions and methods for reducing blood cholesterol |
| EP0102416A1 (en) | 1982-08-23 | 1984-03-14 | Nutrisearch Company | Blends of egg albumen and whey protein of improved gel strength |
| US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| KR930702000A (ko) * | 1990-11-24 | 1993-09-08 | 데이빗 로버츠 | 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용 |
| CN1315473C (zh) | 1997-03-17 | 2007-05-16 | 英国技术集团国际有限公司 | 治疗组合物 |
| CN1131237C (zh) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| BR9909110A (pt) * | 1998-03-26 | 2000-12-12 | Phytopharm Plc | Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo |
| GB9905275D0 (en) | 1999-03-08 | 1999-04-28 | Phytopharm Ltd | Treatment of conditions associated with membrane-bound receptors and their function |
| GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| DK1123094T3 (da) | 1998-09-15 | 2007-08-20 | Btg Int Ltd | Terapeutiske præparater (II) |
| GB2347676A (en) * | 1999-03-08 | 2000-09-13 | Phytopharm Plc | Screening method |
| GB9923078D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| NZ535093A (en) * | 2002-03-27 | 2006-09-29 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
| PL213697B1 (pl) * | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
| US20070041924A1 (en) * | 2005-08-19 | 2007-02-22 | Bioderm Research | Sebum Control Compositions Based on Saponins and Sapogenins |
| US20120034193A1 (en) * | 2009-01-24 | 2012-02-09 | Daryl Rees | Treatment of neurotrophic factor mediated disorders |
-
2011
- 2011-07-20 US US13/811,344 patent/US20130210786A1/en not_active Abandoned
- 2011-07-20 MX MX2013000760A patent/MX2013000760A/es not_active Application Discontinuation
- 2011-07-20 EA EA201390070A patent/EA201390070A1/ru unknown
- 2011-07-20 CN CN2011800412824A patent/CN103189056A/zh active Pending
- 2011-07-20 WO PCT/GB2011/051376 patent/WO2012010896A1/en not_active Ceased
- 2011-07-20 KR KR1020137004015A patent/KR20130043197A/ko not_active Withdrawn
- 2011-07-20 CA CA2805693A patent/CA2805693A1/en not_active Abandoned
- 2011-07-20 AU AU2011281336A patent/AU2011281336B2/en not_active Ceased
- 2011-07-20 JP JP2013520218A patent/JP2013543482A/ja active Pending
- 2011-07-20 SG SG2013003272A patent/SG187090A1/en unknown
- 2011-07-20 EP EP11738032.9A patent/EP2595621A1/en not_active Withdrawn
- 2011-07-20 BR BR112013001422A patent/BR112013001422A2/pt not_active IP Right Cessation
-
2013
- 2013-02-18 ZA ZA2013/01231A patent/ZA201301231B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013000760A (es) | 2013-10-28 |
| ZA201301231B (en) | 2014-04-30 |
| SG187090A1 (en) | 2013-02-28 |
| KR20130043197A (ko) | 2013-04-29 |
| US20130210786A1 (en) | 2013-08-15 |
| JP2013543482A (ja) | 2013-12-05 |
| CA2805693A1 (en) | 2012-01-26 |
| BR112013001422A2 (pt) | 2019-09-24 |
| CN103189056A (zh) | 2013-07-03 |
| WO2012010896A1 (en) | 2012-01-26 |
| AU2011281336A1 (en) | 2013-01-31 |
| AU2011281336B2 (en) | 2015-03-05 |
| EP2595621A1 (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390070A1 (ru) | Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| BR112015020466A2 (pt) | inibidores de cdc7 | |
| EA201890641A2 (ru) | СТИМУЛЯТОРЫ sGC | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| MY180626A (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| EA201001331A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
| EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
| EA200801551A1 (ru) | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы | |
| ECSP088852A (es) | Azolopirimidinas como inhibidores de la actividad canabinoidea 1 | |
| MX2014012881A (es) | 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]am ino]pirazina-2-carbonitrilo y usos terapeuticos del mismo. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| GEAP201814485A (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| EA201791225A1 (ru) | Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей | |
| AU2013260056A8 (en) | Compounds with TRPV4 activity, compositions and associated methods thereof | |
| TR201908151T4 (tr) | İzoindolin türevleri. |